Biktarvy - Revision history

Alexander Berchansky at 14:13, 29 August 2023

Alexander Berchansky — Tue, 29 Aug 2023 14:13:32 GMT

←Older revision		Revision as of 14:13, 29 August 2023
Line 2:		Line 2:
	[[Bictegravir]]/[[emtricitabine]]/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.<ref name="a4">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=664cb8f0-1f65-441b-b0d9-ba3d798be309 "Biktarvy- bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate tablet".] DailyMed. 8 August 2019. Retrieved 7 March 2020.</ref> It was approved for use in the United States in February 2018,<ref name="a5">[https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210251Orig1s000TOC.cfm "Drug Approval Package: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) Tablets".] U.S. Food and Drug Administration (FDA). 19 March 2018. Retrieved 7 March 2020.</ref><ref name="a6">[https://www.businesswire.com/news/home/20180207006071/en/U.S.-Food-Drug-Administration-Approves-Gilead%E2%80%99s-Biktarvy%C2%AE "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection"] (Press release). Gilead. 7 February 2018.</ref> and for use in the European Union in June 2018.<ref name="a7">[https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy "Biktarvy EPAR".] European Medicines Agency (EMA). 21 January 2020. Retrieved 7 March 2020.</ref>		[[Bictegravir]]/[[emtricitabine]]/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.<ref name="a4">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=664cb8f0-1f65-441b-b0d9-ba3d798be309 "Biktarvy- bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate tablet".] DailyMed. 8 August 2019. Retrieved 7 March 2020.</ref> It was approved for use in the United States in February 2018,<ref name="a5">[https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210251Orig1s000TOC.cfm "Drug Approval Package: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) Tablets".] U.S. Food and Drug Administration (FDA). 19 March 2018. Retrieved 7 March 2020.</ref><ref name="a6">[https://www.businesswire.com/news/home/20180207006071/en/U.S.-Food-Drug-Administration-Approves-Gilead%E2%80%99s-Biktarvy%C2%AE "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection"] (Press release). Gilead. 7 February 2018.</ref> and for use in the European Union in June 2018.<ref name="a7">[https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy "Biktarvy EPAR".] European Medicines Agency (EMA). 21 January 2020. Retrieved 7 March 2020.</ref>

-	[[Bictegravir]]:	+	[[Bictegravir]] (integrase inhibitor):
	*<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]).		*<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]).
	*<scene name='98/989308/Overall/4'>Bictegravir inhibits integrase</scene>.		*<scene name='98/989308/Overall/4'>Bictegravir inhibits integrase</scene>.

-	[[Emtricitabine]]:	+	[[Emtricitabine]] (nucleotide reverse transcriptase inhibitor):
	*<scene name='95/959998/Cv/2'>Emtricitabine</scene>.		*<scene name='95/959998/Cv/2'>Emtricitabine</scene>.
	*<scene name='95/959998/Cv/4'>Emtricitabine binding site</scene> at reverse transcriptase ([[2no6]]). Water molecules are shown as red spheres.		*<scene name='95/959998/Cv/4'>Emtricitabine binding site</scene> at reverse transcriptase ([[2no6]]). Water molecules are shown as red spheres.

-	Tenofovir alafenamide:	+	Tenofovir alafenamide (nucleotide reverse transcriptase inhibitor):
	*<scene name='98/989318/Cv/1'>Tenofovir alafenamide</scene>.		*<scene name='98/989318/Cv/1'>Tenofovir alafenamide</scene>.
	</StructureSection>		</StructureSection>
	== References ==		== References ==
	<references/>		<references/>

Alexander Berchansky at 12:58, 29 August 2023

Alexander Berchansky — Tue, 29 Aug 2023 12:58:15 GMT

←Older revision		Revision as of 12:58, 29 August 2023
Line 9:		Line 9:
	*<scene name='95/959998/Cv/2'>Emtricitabine</scene>.		*<scene name='95/959998/Cv/2'>Emtricitabine</scene>.
	*<scene name='95/959998/Cv/4'>Emtricitabine binding site</scene> at reverse transcriptase ([[2no6]]). Water molecules are shown as red spheres.		*<scene name='95/959998/Cv/4'>Emtricitabine binding site</scene> at reverse transcriptase ([[2no6]]). Water molecules are shown as red spheres.
		+
		+	Tenofovir alafenamide:
		+	*<scene name='98/989318/Cv/1'>Tenofovir alafenamide</scene>.
	</StructureSection>		</StructureSection>
	== References ==		== References ==
	<references/>		<references/>

Alexander Berchansky at 12:47, 29 August 2023

Alexander Berchansky — Tue, 29 Aug 2023 12:47:22 GMT

←Older revision		Revision as of 12:47, 29 August 2023
Line 6:		Line 6:
	*<scene name='98/989308/Overall/4'>Bictegravir inhibits integrase</scene>.		*<scene name='98/989308/Overall/4'>Bictegravir inhibits integrase</scene>.

		+	[[Emtricitabine]]:
		+	*<scene name='95/959998/Cv/2'>Emtricitabine</scene>.
		+	*<scene name='95/959998/Cv/4'>Emtricitabine binding site</scene> at reverse transcriptase ([[2no6]]). Water molecules are shown as red spheres.
	</StructureSection>		</StructureSection>
	== References ==		== References ==
	<references/>		<references/>

Alexander Berchansky at 12:45, 29 August 2023

Alexander Berchansky — Tue, 29 Aug 2023 12:45:06 GMT

←Older revision		Revision as of 12:45, 29 August 2023
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'>		<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'>
	[[Bictegravir]]/[[emtricitabine]]/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.<ref name="a4">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=664cb8f0-1f65-441b-b0d9-ba3d798be309 "Biktarvy- bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate tablet".] DailyMed. 8 August 2019. Retrieved 7 March 2020.</ref> It was approved for use in the United States in February 2018,<ref name="a5">[https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210251Orig1s000TOC.cfm "Drug Approval Package: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) Tablets".] U.S. Food and Drug Administration (FDA). 19 March 2018. Retrieved 7 March 2020.</ref><ref name="a6">[https://www.businesswire.com/news/home/20180207006071/en/U.S.-Food-Drug-Administration-Approves-Gilead%E2%80%99s-Biktarvy%C2%AE "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection"] (Press release). Gilead. 7 February 2018.</ref> and for use in the European Union in June 2018.<ref name="a7">[https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy "Biktarvy EPAR".] European Medicines Agency (EMA). 21 January 2020. Retrieved 7 March 2020.</ref>		[[Bictegravir]]/[[emtricitabine]]/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.<ref name="a4">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=664cb8f0-1f65-441b-b0d9-ba3d798be309 "Biktarvy- bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate tablet".] DailyMed. 8 August 2019. Retrieved 7 March 2020.</ref> It was approved for use in the United States in February 2018,<ref name="a5">[https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210251Orig1s000TOC.cfm "Drug Approval Package: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) Tablets".] U.S. Food and Drug Administration (FDA). 19 March 2018. Retrieved 7 March 2020.</ref><ref name="a6">[https://www.businesswire.com/news/home/20180207006071/en/U.S.-Food-Drug-Administration-Approves-Gilead%E2%80%99s-Biktarvy%C2%AE "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection"] (Press release). Gilead. 7 February 2018.</ref> and for use in the European Union in June 2018.<ref name="a7">[https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy "Biktarvy EPAR".] European Medicines Agency (EMA). 21 January 2020. Retrieved 7 March 2020.</ref>
		+
		+	[[Bictegravir]]:
		+	*<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]).
		+	*<scene name='98/989308/Overall/4'>Bictegravir inhibits integrase</scene>.

	</StructureSection>		</StructureSection>
	== References ==		== References ==
	<references/>		<references/>

Alexander Berchansky at 12:43, 29 August 2023

Alexander Berchansky — Tue, 29 Aug 2023 12:43:15 GMT

←Older revision		Revision as of 12:43, 29 August 2023
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'>		<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'>
-	[[Bictegravir]]/[[emtricitabine]]/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.[4] It was approved for use in the United States in February 2018,[5][6] and for use in the European Union in June 2018.[7]	+	[[Bictegravir]]/[[emtricitabine]]/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.<ref name="a4">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=664cb8f0-1f65-441b-b0d9-ba3d798be309 "Biktarvy- bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate tablet".] DailyMed. 8 August 2019. Retrieved 7 March 2020.</ref> It was approved for use in the United States in February 2018,<ref name="a5">[https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210251Orig1s000TOC.cfm "Drug Approval Package: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) Tablets".] U.S. Food and Drug Administration (FDA). 19 March 2018. Retrieved 7 March 2020.</ref><ref name="a6">[https://www.businesswire.com/news/home/20180207006071/en/U.S.-Food-Drug-Administration-Approves-Gilead%E2%80%99s-Biktarvy%C2%AE "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection"] (Press release). Gilead. 7 February 2018.</ref> and for use in the European Union in June 2018.<ref name="a7">[https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy "Biktarvy EPAR".] European Medicines Agency (EMA). 21 January 2020. Retrieved 7 March 2020.</ref>

	</StructureSection>		</StructureSection>
	== References ==		== References ==
	<references/>		<references/>

Alexander Berchansky: New page: Bictegravir/emtricitabine/tenofovir alafenamide, sold under the brand...

Alexander Berchansky — Tue, 29 Aug 2023 12:35:47 GMT

New page: <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'> Bictegravir/emtricitabine/tenofovir alafenamide, sold under the brand...

New page

<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'>
[[Bictegravir]]/[[emtricitabine]]/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.[4] It was approved for use in the United States in February 2018,[5][6] and for use in the European Union in June 2018.[7]

</StructureSection>
== References ==
<references/>